Lenalidomide Mylan

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

леналидомид

Available from:

Mylan Ireland Limited

ATC code:

L04AX07

INN (International Name):

lenalidomide

Therapeutic group:

Имуносупресори

Therapeutic area:

Множествена миелома

Therapeutic indications:

Multiple myelomaLenalidomide Mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Lenalidomide Mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. Lenalidomide Mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Follicular lymphomaLenalidomide Mylan in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1-3a).

Product summary:

Revision: 8

Authorization status:

упълномощен

Authorization date:

2020-12-18

Patient Information leaflet

                                97
Б. ЛИСТОВКА
98
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПАЦИЕНТА
ЛЕНАЛИДОМИД
MYLAN 2,5 MG ТВЪРДИ КАПСУЛИ
ЛЕНАЛИДОМИД
MYLAN 5 MG ТВЪРДИ КАПСУЛИ
ЛЕНАЛИДОМИД
MYLAN 7,5 MG ТВЪРДИ КАПСУЛИ
ЛЕНАЛИДОМИД
MYLAN 10 MG ТВЪРДИ КАПСУЛИ
ЛЕНАЛИДОМИД
MYLAN 15 MG ТВЪРДИ КАПСУЛИ
ЛЕНАЛИДОМИД
MYLAN 20 MG ТВЪРДИ КАПСУЛИ
ЛЕНАЛИДОМИД
MYLAN 25 MG ТВЪРДИ КАПСУЛИ
леналидомид (lenalidomide)
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА,
ПРЕДИ ДА ЗАПОЧНЕТЕ ДА ПРИЕМАТЕ ТОВА
ЛЕКАРСТВО,
ТЪЙ КАТО ТЯ СЪДЪРЖА ВАЖНА ЗА ВАС
ИНФОРМАЦИЯ.
-
Запазете тази листовка. Може да се
наложи да я прочетете отново.
-
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар,
фармацевт или
медицинска сестра.
-
Това лекарство е предписано лично на
Вас. Не го преотстъпвайте на други
хора. То може
да им навреди, независимо че
признаците на тяхното заболяване са
същите като Вашите.
-
Ако получите някакви нежелани
реакции, уведомете Вашия лекар или
фармацевт. Това
включва и всички възможни нежелани
реакции, неописани в тази листовка.
Вижте
точка 4.
КАКВО СЪДЪРЖА ТАЗИ ЛИСТОВКА
:
1.
Какво представлява Леналидомид Mylan
и за какво се използва
2.
Какво трябва да знаете, преди да
приемете Леналидомид Mylan
3.
Как да приемaте Леналидомид M
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Леналидомид Mylan 2,5 mg твърди капсули
Леналидомид Mylan 5 mg твърди капсули
Леналидомид Mylan 7,5 mg твърди капсули
Леналидомид Mylan 10 mg твърди капсули
Леналидомид Mylan 15 mg твърди капсули
Леналидомид Mylan 20 mg твърди капсули
Леналидомид Mylan 25 mg твърди капсули
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
_ _
Леналидомид Mylan 2,5 mg твърди капсули
Всяка капсула съдържа 2,5 mg леналидомид
(lenalidomide).
Леналидомид Mylan 5 mg твърди капсули
Всяка капсула съдържа 5 mg леналидомид
(lenalidomide).
Леналидомид Mylan 7,5 mg твърди капсули
Всяка капсула съдържа 7,5 mg леналидомид
(lenalidomide).
Леналидомид Mylan 10 mg твърди капсули
Всяка капсула съдържа 10 mg леналидомид
(lenalidomide).
Леналидомид Mylan 15 mg твърди капсули
Всяка капсула съдържа 15 mg леналидомид
(lenalidomide).
Леналидомид Mylan 20 mg твърди капсули
Всяка капсула съдържа 20 mg леналидомид
(lenalidomide).
Леналидомид Mylan 25 mg твърди капсули
Всяка капсула съдържа 25 mg леналидомид
(lenalidomide).
За пълния списък на помощните
вещества вижте точка 6.1.
3.
ЛЕКАРСТВЕНА ФОРМА
Твърда капсула (капсула)
Леналидомид Mylan 2,5 mg твърди капсули
Зелено-бели капсули, размер 4, 14 mm,
маркирани с “MYLAN/LL 2,5”.
Л
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 12-07-2023
Public Assessment Report Public Assessment Report Spanish 07-01-2021
Patient Information leaflet Patient Information leaflet Czech 12-07-2023
Public Assessment Report Public Assessment Report Czech 07-01-2021
Patient Information leaflet Patient Information leaflet Danish 12-07-2023
Public Assessment Report Public Assessment Report Danish 07-01-2021
Patient Information leaflet Patient Information leaflet German 12-07-2023
Public Assessment Report Public Assessment Report German 07-01-2021
Patient Information leaflet Patient Information leaflet Estonian 12-07-2023
Public Assessment Report Public Assessment Report Estonian 07-01-2021
Patient Information leaflet Patient Information leaflet Greek 12-07-2023
Public Assessment Report Public Assessment Report Greek 07-01-2021
Patient Information leaflet Patient Information leaflet English 12-07-2023
Public Assessment Report Public Assessment Report English 07-01-2021
Patient Information leaflet Patient Information leaflet French 12-07-2023
Public Assessment Report Public Assessment Report French 07-01-2021
Patient Information leaflet Patient Information leaflet Italian 12-07-2023
Public Assessment Report Public Assessment Report Italian 07-01-2021
Patient Information leaflet Patient Information leaflet Latvian 12-07-2023
Public Assessment Report Public Assessment Report Latvian 07-01-2021
Patient Information leaflet Patient Information leaflet Lithuanian 12-07-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 12-07-2023
Public Assessment Report Public Assessment Report Lithuanian 07-01-2021
Patient Information leaflet Patient Information leaflet Hungarian 12-07-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 12-07-2023
Public Assessment Report Public Assessment Report Hungarian 07-01-2021
Patient Information leaflet Patient Information leaflet Maltese 12-07-2023
Public Assessment Report Public Assessment Report Maltese 07-01-2021
Patient Information leaflet Patient Information leaflet Dutch 12-07-2023
Public Assessment Report Public Assessment Report Dutch 07-01-2021
Patient Information leaflet Patient Information leaflet Polish 12-07-2023
Public Assessment Report Public Assessment Report Polish 07-01-2021
Patient Information leaflet Patient Information leaflet Portuguese 12-07-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 12-07-2023
Public Assessment Report Public Assessment Report Portuguese 07-01-2021
Patient Information leaflet Patient Information leaflet Romanian 12-07-2023
Public Assessment Report Public Assessment Report Romanian 07-01-2021
Patient Information leaflet Patient Information leaflet Slovak 12-07-2023
Public Assessment Report Public Assessment Report Slovak 07-01-2021
Patient Information leaflet Patient Information leaflet Slovenian 12-07-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 12-07-2023
Public Assessment Report Public Assessment Report Slovenian 07-01-2021
Patient Information leaflet Patient Information leaflet Finnish 12-07-2023
Public Assessment Report Public Assessment Report Finnish 07-01-2021
Patient Information leaflet Patient Information leaflet Swedish 12-07-2023
Public Assessment Report Public Assessment Report Swedish 07-01-2021
Patient Information leaflet Patient Information leaflet Norwegian 12-07-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 12-07-2023
Patient Information leaflet Patient Information leaflet Icelandic 12-07-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 12-07-2023
Patient Information leaflet Patient Information leaflet Croatian 12-07-2023
Public Assessment Report Public Assessment Report Croatian 07-01-2021

Search alerts related to this product